Subcutaneous version of Roche's blockbuster cancer drug meets study goals
According to the firm, positive phase III data might be enough to have cancer immunotherapy Tecentriq approved as an under-the-skin injection in the EU and the US.
by christian bundgaard, translated by daniel pedersen
Roche has had overwhelming success with PD-L1 inhibitor Tecentriq (atezolizumab) as a treatment for locally advanced or metastatic non-small cell lung cancer (NSCLC) – in just a few years, the drug has managed to pass the USD 1bn dollar annual revenue threshold, earning it the blockbuster title.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Roche to reshuffle management and board
For subscribers
